

Teaching lectures

973

PROBLEMS, OF DRUG DEVELOPMENT AND REGISTRATION IN EUROPE

M. Marty

Department of Medical Oncology, Saint Louis Hosp., Paris, France

The current European Application Procedures—Centralized, Decentralized, and National—are well adapted to Drug Registration in the EU. The specific problems of anticancer agents—phase I trials in patients, lack of well accepted surrogate end-points, value of phase III single agents trials, role of Quality of Life measures, general use in the context of combination and multimodality therapy—are poorly understood by some Agencies. A better interaction between Oncologists and Agencies is needed as well as clarification of these points.

Drug development raises more questions. (1) Only a minority of Early Clinical Trials are performed in Europe. (2) Few indications are targetted—Breast, Lung, Colorectal, Ovarian Carcinomas. (3) Less frequent cancers are not studied as soon as registration is obtained in one major indication therefore accounting for wide off-label prescriptions. A process allowing for alteration of the SPC on the basis of well conducted Institutional trials should be considered together with appropriate cost adjustments. (4) Pharmacovigilance of antineoplastic agents is almost non existent. (5) Further trials addressing dose-intensity as well as atypical combinations (i.e double alkylation) are examples of non approved procedures which ultimately might legally involve Oncologists.

As Registration can be acquired early, and further use of the agent can be looked without modification of the SPC, one can expect that Social Security and/or Insurances will limit the use of recently approved agents to the legal indications. It is thus the responsibility of the Oncology Community to (1) Participate in prospective trials; (2) organize consensus conference to define the State of the Art in the use of anticancer agents.

974

NEW DEVELOPMENTS OF NUCLEAR MEDICINE IN DIAGNOSIS AND TREATMENT: THE PRETARGETING APPROACH

G. Paganelli

European Institute of Oncology, Milan, Italy

Specific targeting of radioactive agents to tumor cells has been a major goal of the *in vivo* use of monoclonal antibodies (MoAb) for diagnostic and therapeutic purposes. However, only a relatively small amount of the injected dose of MoAbs is bound by the tumor, while MoAb conjugated to radioisotope keep circulating in the blood stream and in normal tissue. These considerations have led to strategies of tumor pretargeting, where MoAb and radiolabel are administered separately. One of these strategies is based on the avidin-biotin system. With the so-called three-step method, injection of non-radioactive biotinylated MoAbs (first step) is followed after 1 day by "cold" avidin (second step). If radioactively labelled biotin is now administered (third step), it binds selectively to avidin and therefore to the tumour, including colon and lung cancers, gliomas, ocular and cutaneous melanomas and apudomas. The method has shown to be safe, reliable and of clinical utility since an overall sensitivity of 88% with 94% specificity and 84% accuracy was demonstrated. These encouraging results have prompted us to initiate a therapy trial using biotin-LC-DOTA labeled with Y-90.

975

GENETIC ALTERATIONS IN BREAST CANCER

R. Lidereau

Laboratoire d'Oncogénétique, Centre René Huguenin, 92211 St-Cloud, France

The etiology of breast cancer involves a complex interplay of various factors, including genetic alterations. Many studies have been devoted to the identification and characterization of mutations that occur frequently during breast tumorigenesis. The major types of genetic abnormalities frequently observed in breast tumor DNAs are amplification of proto-oncogenes (*MYC*, *ERBB2*) and chromosome band 11q13, mutation of *TP53*, and loss of heterozygosity (chromosomes and chromosome arms 1, 3p, 6q, 7q, 8p, 11, 13q, 16q, 17, 18q and 22q). Genetic deletions and mutations could inactivate tumor-suppressor genes. Recently, linkage analysis of large families with a predisposition to breast cancer have been performed in order to map breast cancer susceptibility genes (*TP53*, *BRCA1*, *BRCA2*, ...). The findings have thrown light on the molecular mechanisms of breast cancer, and have enabled various genetic markers to be used in clinical oncology.

976

THE ROLE OF BRACHYTHERAPY IN THE TREATMENT OF CERVICAL CARCINOMA

C. Haie-Meder, A. Gerbaulet, E. Lartigau, H. Marsiglia, C. Lhomme, D. Castaigne

Department of Radiotherapy, Institut Gustave-Roussy, 94800 Villejuif, France

Brachytherapy (BT) plays an essential role in the local control of cervix carcinoma. Numerous applicators have been designed for intracavitary BT. Among them, custom-made vaginal moulds fit the anatomy of the vagina and the topography of the tumor. Dose prescription has been frequently reported at a single point, the Manchester point A. More recently, ICRU Report 38 has defined a reference volume of the 60 Gy isodose, specific envelope reference points associated with normal tissues (bladder, rectum, pelvic side walls). The ICRU recommendations also include the description of the technique. The aim of this Report 38 is to uniform the dosimetry report and to find correlations between dosimetric characteristics and complications.

Interstitial BT techniques were developed for bulky parametrial or vaginal involvement or vaginal or limited central recurrences. A higher incidence of severe complications was observed with this approach.

Traditional dose-rate in gynecological BT is low-dose rate BT. More recently, high-dose rate BT was used in cervical carcinoma. Two randomized trials showed results in favour of high-dose rate BT, but other authors have described a higher incidence of complications when the dose rate increases.

More clinical studies are required to better define the exact role of high dose rate in the therapeutic approach of cervical carcinoma.

977

CANCER IN THE ELDERLY

S. Monfardini

CRO, Istituto Nazionale Tumori Centroeuropeo, Aviano, PN, Italy

Although cancer is not an inevitable consequence of aging, malignant diseases, especially solid tumors, occur disproportionately in the subset of the population aged 65 years and older. Thus, because the older population are rapidly expanding in most industrial nations, there is a high potential in these countries for many more persons to have cancer. Although two thirds of all cancer deaths occur in the 65-and-older age segment of the population, there have been so far only a few descriptive,

cross-sectional retrospective and prospective studies on cancer in the elderly. More interest and activity in research on aging and cancer has however been evidenced in the 1990s. Directions for the future could be as follows:

1. Establish multidisciplinary clinical trial design teams to address the challenging issues of old age and cancer therapy in a prospective study methodology.
2. Focus on the pharmacokinetics and drug sensitivity of elderly cancer patients to assess and deal with differences in drug metabolism.
3. Introduce in clinical oncology "multidimensional geriatric assessment" methods for pretreatment and follow-up evaluation of elderly cancer patients.
4. Develop special "patterns of care" studies of the major tumors to characterize the treatment of older cancer patients who, because of an excess of comorbid conditions, are not eligible for placement on clinical trials.
5. Increase the cooperation of geriatricians with clinical oncologists since cancer is one of the more prevalent chronic diseases of their older patients.

978

LIVER TRANSPLANTATION FOR MALIGNANT DISEASE

K. J. Oldhafer

Department of Surgery, Hannover Medical School, Germany

Although resection remains the treatment of choice in liver cancer, a single center experience with 198 patients reveals that liver transplantation continues to keep its role as a therapeutic option for selected patients. At present "favourable" indications are International Union against Cancer (UICC)-stage II hepatocellular carcinoma as well as the subtype fibrolamellar carcinoma, furthermore uncommon tumors such as epitheloid hemangioendothelioma, hepatoblastoma and liver metastasis from neuroendocrine tumors. Due to unsatisfying results intrahepatic bile duct-, stage III and IV hepatocellular carcinoma, hemangiosarcoma and liver metastases from nonendocrine primaries should be excluded from liver transplantation alone. For these advanced tumors especially in case of extrahepatic involvement combination of liver transplantation and multivisceral resection has been proven feasible. However, a significant improvement in patient survival may only be expected by presently investigated multimodality treatment protocols which will require further randomized studies.